english.prescrire.org > Spotlight > 100 most recent > Alectinib (Alecensa°) as first-line treatment in advanced or metastatic ALK-positive non-small cell lung cancer

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Alectinib (Alecensa°) as first-line treatment in advanced or metastatic ALK-positive non-small cell lung cancer

 Marketing Authorisations  The initial marketing authorisation for the use of alectinib in patients with advanced or metastatic non-small cell lung cancer harbouring an ALK mutation was based on the preliminary results of two comparative randomised trials, called "Alex" and "Alur". More results from these trials, with longer follow-up, have become available since the evaluation published in our French edition in 2018.
Full article available for download by subscribers

 ©Prescrire 1 November 2025

Source: "Alectinib (Alecensa°) as first-line treatment in advanced or metastatic ALK-positive non-small cell lung cancer" Prescrire Int 2025; 34 (275): 266. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information